肿瘤浸润B细胞与免疫治疗

doi:10.11904/j.issn.1002-3070.2022.06.004

摘要/Abstract

摘要： B细胞是肿瘤微环境的重要成分,然而,B细胞对肿瘤进展及治疗响应的影响目前仍然存在争议,这反映了肿瘤浸润B细胞(Tumor infiltrating B cells,TIL-Bs)亚群的异质性。事实上,这些TIL-Bs随着所处的免疫微环境向不同的方向极化进而获得不同的表型及功能,同时也反向塑造着微环境的组成及类型,最终导致了截然不同的临床预后。本文总结了TIL-Bs的组成特征及形成机制。进一步结合临床试验及临床前研究,我们尝试解释TIL-Bs的异质性对肿瘤免疫治疗效果的影响。阐明肿瘤中B细胞亚群的组成、产生和相关免疫网络的性质对于全面了解肿瘤中的B细胞反应,设计更有效的癌症免疫疗法具有重要意义。

关键词: 肿瘤浸润B细胞, 免疫微环境, 肿瘤免疫治疗

Abstract: B cells are an critical component of the tumor microenvironment.However,the impact of B cells on tumor progression and treatment response is still controversial,reflecting the heterogeneity of tumor infiltrating B cells(TIL-Bs)subsets.In fact,these TIL-Bs are polarized in different directions with the immune microenvironment in which they are located to obtain different phenotypes and functions,and at the same time reversely shape the composition and type of the microenvironment,eventually leading to completely different clinical outcomes.This article summarizes the composition characteristics and formation mechanism of TIL-Bs.Further,combined with clinical trials and preclinical studies,we try to explain the influence of TIL-Bs heterogeneity on the effect of tumor immunotherapy.Elucidating the composition,generation,and nature of associated immune networks of B cell subsets in tumors are of great importance for a comprehensive understanding of B cell responses in tumors and for the design of more effective cancer immunotherapies.

Key words: Tumor infiltrating B cells, Immune microenvironment, Tumor immunotherapy

中图分类号:

R73.36⁺2

曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.

CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies[J]. Journal of Practical Oncology, 2022, 36(6): 507-512.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.004

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/507

参考文献

1 Abril-rodriguez G,Ribas A.Snap shot:immune checkpoint inhibitors[J].Cancer Cell,2017,31(6):848.
2 Das S,Johnson DB.Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors[J].J Immunother Cancer,2019,7(1):306.
3 Zhang Z,Ma L,Goswami S,et al.Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma[J].Oncoimmunology,2019,8(4):e1571388.
4 Wei Y,Huang CX,Xiao X,et al.B cell heterogeneity,plasticity,and functional diversity in cancer microenvironments[J].Oncogene,2021,40(29):4737-4745.
5 Hu Q,Hong Y,Qi P,et al.Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling[J].Nat Commun,2021,12(1):2186.
6 Qian J,Olbrecht S,Boeckx B,et al.A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling[J].Cell Res,2020,30(9):745-762.
7 Griss J,Bauer W,Wagner C,et al.B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma[J].Nat Commun,2019,10(1):4186.
8 Wei Y,Lao XM,Xiao X,et al.Plasma cell polarization to the immunoglobulin G phenotype in hepatocellular carcinomas involves epigenetic alterations and promotes hepatoma progression in mice[J].Gastroenterology,2019,156(6):1890-1904.
9 Chen J,Tan Y,Sun F,et al.Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer[J].Genome Biol,2020,21(1):152.
10 Shalapour S,Font-burgada J,Di Caro G,et al.Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy[J].Nature,2015,521(7550):94-98.
11 Weiner AB,Vidotto T,Liu Y,et al.Plasma cells are enriched in localized prostate cancer in black men and are associated with improved outcomes[J].Nat Commun,2021,12(1):935.
12 Crawford G,Hayes MD,Seoane RC,et al.Epithelial damage and tissue γδ T cells promote a unique tumor-protective IgE response[J].Nat Immunol,2018,19(8):859-870.
13 André P,Denis C,Soulas C,et al.Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells[J].Cell,2018,175(7):1731-1743.
14 Sharonov GV,Serebrovskaya EO,Yuzhakova DV,et al.B cells,plasma cells and antibody repertoires in the tumour microenvironment[J].Nat Rev Immunol,2020,20(5):294-307.
15 Boross P,Lohse S,Nederend M,et al.IgA EGFR antibodies mediate tumour killing in vivo[J].EMBO Mol Med,2013,5(8):1213-1226.
16 Borrok MJ,Luheshi NM,Beyaz N,et al.Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI(CD89)binding[J].MAbs,2015,7(4):743-751.
17 Valerius T,Stockmeyer B,Van Spriel AB,et al.FcalphaRI(CD89)as a novel trigger molecule for bispecific antibody therapy[J].Blood,1997,90(11):4485-4492.
18 Brandsma AM,Bondza S,Evers M,et al.Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG[J].Front Immunol,2019,10:704.
19 Josephs DH,Bax HJ,Dodev T,et al.Anti-Folate receptor-α IgE but not IgG recruits Macrophages to attack tumors via TNFα/MCP-1 signaling[J].Cancer Res,2017,77(5):1127-1141.
20 Gould HJ,Mackay GA,Karagiannis SN,et al.Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma[J].Eur J Immunol,1999,29(11):3527-3537.
21 Quarta A,Bernareggi D,Benigni F,et al.Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles:a full study to provide the proof of principle from in vitro to in vivo[J].Nanoscale,2015,7(6):2336-2351.
22 Patil NS,Nabet BY,Müller S,et al.Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer[J].Cancer Cell,2022,40(3):289-300.
23 Leader AM,Grout JA,Maier BB,et al.Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification[J].Cancer Cell,2021,39(12):1594-1609.
24 Teillaud JL,Dieu-nosjean MC.Intratumoral plasma cells:More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?[J].Cancer Cell,2022,40(3):240-243.
25 Lino AC,Dang VD,Lampropoulou V,et al.LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells[J].Immunity,2018,49(1):120-133.
26 Matsumoto M,Baba A,Yokota T,et al.Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation[J].Immunity,2014,41(6):1040-1051.
27 Blair PA,Norea LY,Flores-borja F,et al.CD19⁽⁺⁾CD24^(hi)CD38^(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients[J].Immunity,2010,32(1):129-140.
28 Flores-Borja F,Bosma A,Ng D,et al.CD19⁺CD24^hiCD38^hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation[J].Sci Transl Med,2013,5(173):173ra23.
29 Krejcik J,Casneuf T,Nijhof IS,et al.Daratumumab depletes CD38⁺ immune regulatory cells,promotes T-cell expansion,and skews T-cell repertoire in multiple myeloma[J].Blood,2016,128(3):384-394.
30 Zhang L,Tai YT,Ho M,et al.Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu[J].Blood Cancer J,2017,7(3):e547.
31 Wang RX,Yu CR,Dambuza IM,et al.Interleukin-35 induces regulatory B cells that suppress autoimmune disease[J].Nat Med,2014,20(6):633-641.
32 Choi JK,Egwuagu CE.Interleukin 35 regulatory B Cells[J].J Mol Biol,2021,433(1):166607.
33 Wang K,Liu J,Li J.IL-35-producing B cells in gastric cancer patients[J].Medicine(Baltimore),2018,97(19):e0710.
34 Olkhanud PB,Damdinsuren B,Bodogai M,et al.Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺T cells to T-regulatory cells[J].Cancer Res,2011,71(10):3505-3515.
35 Mirlekar B,Michaud D,Lee SJ,et al.B cell-derived IL35 drives STAT3-dependent CD8⁽⁺⁾ T-cell exclusion in pancreatic cancer[J].Cancer Immunol Res,2020,8(3):292-308.
36 Barbera-guillem E,Nelson MB,Barr B,et al.B lymphocyte pathology in human colorectal cancer.Experimental and clinical therapeutic effects of partial B cell depletion[J].Cancer Immunol Immunother,2000,48(10):541-549.
37 Theurich S,Schlaak M,Steguweit H,et al.Targeting tumor-infiltrating B cells in cutaneous T-Cell lymphoma[J].J Clin Oncol,2016,34(12):110-116.
38 Bodogai M,Lee Chang C,Wejksza K,et al.Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L[J].Cancer Res,2013,73(7):2127-2138.
39 Aklilu M,Stadler WM,Markiewicz M,et al.Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma[J].Ann Oncol,2004,15(7):1109-1114.
40 Shen L,Li J,Liu Q,et al.Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth[J].J Control Release,2022,343:303-313.
41 Johansson H,Andersson R,Bauden M,et al.Immune checkpoint therapy for pancreatic cancer[J].World J Gastroenterol,2016,22(43):9457-9476.
42 Mirlekar B,Michaud D,Searcy R,et al.IL35 hinders endogenous antitumor T-cell immunity and responsiveness to immunotherapy in pancreatic cancer[J].Cancer Immunol Res,2018,6(9):1014-1024.
43 Avalos AM,Ploegh HL.Early BCR events and antigen capture,processing,and loading on MHC Class II on B Cells[J].Front Immunol,2014,5:92.
44 Wennhold K,Shimabukuro-vornhagen A,Von bergwelt-baildon M.B Cell-based cancer immunotherapy[J].Transfus Med Hemother,2019,46(1):36-46.
45 Hua Z,Hou B.The role of B cell antigen presentation in the initiation of CD4⁺T cell response[J].Immunol Rev,2020,296(1):24-35.
46 Schultze JL,Michalak S,Seamon MJ,et al.CD40-activated human B cells:an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy[J].J Clin Invest,1997,100(11):2757-2765.
47 Ritchie DS,Yang J,Hermans IF,et al.B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8⁽⁺⁾ T-cells[J].Scand J Immunol,2004,60(6):543-551.
48 Wennhold K,Weber TM,Klein-gonzalez N,et al.CD40-activated B cells induce anti-tumor immunity in vivo[J].Oncotarget,2017,8(17):27740-27753.
49 Wennhold K,Thelen M,Schlsse HA,et al.Using antigen-specific B cells to combine antibody and T cell-based cancer immunotherapy[J].Cancer Immunol Res,2017,5(9):730-743.
50 Moutai T,Yamana H,Nojima T,et al.A novel and effective cancer immunotherapy mouse model using antigen-specific B cells selected in vitro[J].PLoS One,2014,9(3):e92732.
51 Winkler J,Tittlbach H,Roesler W,et al.Adoptive transfer of purified donor-B-lymphocytes after allogeneic stem cell transplantation:results from a phase Ⅰ/Ⅱa clinical trial[J].Blood,2016,128(22):502.
52 Laumont CM,Banville AC,Gilardi M,et al.Tumour-infiltrating B cells:immunological mechanisms,clinical impact and therapeutic opportunities[J].Nat Rev Cancer,2022,22(7):414-430.

[1]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[2]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[3]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[4]	付艳丽, 余杨, 卫玮, 邹晶晶, 孙翔. 高危型人乳头状瘤病毒载量和Th1/Th2不均衡表达预测宫颈癌变进程的研究[J]. 实用肿瘤学杂志, 2018, 32(6): 533-537.
[5]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.
[6]	刘洋洋, 谷飞飞, 梁金燕综述, 刘莉审校. 髓源性抑制细胞在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 257-261.
[7]	武丽华, 王东亮, 张艳桥. 髓源性抑制细胞——肿瘤免疫治疗的新靶点[J]. 实用肿瘤学杂志, 2012, 26(4): 369-372.